Tarsus Pharmaceuticals is seeking FDA approval in the US and is listed on the Nasdaq stock exchange.
11 reports, 5 independent
Updated Sun 00:00
No new developments lately
Reached 3 outlets in its first 24 hours
- Reports
- 11
- Developments
- 6
- Repetition
- 55%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tarsus Pharmaceuticals is seeking FDA approval in the US and is listed on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Tarsus Pharmaceuticals appoints new leadership and launches a branded advertising campaign featuring John Cena.1 source
Tarsus Pharmaceuticals appoints Bobby Azamian as CEO and launches a celebrity campaign featuring John Cena.1 source
- A spokesperson issued a warning regarding issues within the pharmaceutical supply chain.Sub-event
Tarsus Pharmaceuticals is seeking FDA approval while being listed on Nasdaq.1 source
Tarsus product received FDA approval in the US and participated in a Wells Fargo conference.1 source
Tarsus Pharmaceuticals is located in Irvine, California.1 source
Keep exploring
The entities involved
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- RedHill Biopharma Ltd., headquartered in Tel Aviv, is a company publicly traded on the Nasdaq exchange with its lead product approved by the FDA.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- manilatimes.net
- dailypolitical.com
- manilatimes.net
- manilatimes.net
- GlobeNewswireTarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to particip
- GlobeNewswireTarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase
- GlobeNewswireTarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that
- Simply Wall St.Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Path To Profitability With the business potentially at an important milestone, we thought we'd take a closer look at Tarsus Pharmaceuticals, Inc.'s (NASDA